The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate
IDH2 protein mutant form results in increased abundance of glucose-1-phosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of glucose-1-phosphate]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate] APP protein mutant form results in decreased abundance of Glucose-6-Phosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of Glucose-6-Phosphate]
GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of Glucose-6-Phosphate]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of Glucose-6-Phosphate]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of Glucose-6-Phosphate] MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Glucose-6-Phosphate]
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA
PFKFB1 gene mutant form results in increased abundance of Glucose-6-Phosphate PFKFB1 gene mutant form inhibits the reaction [Metformin results in decreased abundance of Glucose-6-Phosphate metabolite]
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to 4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrile] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in increased abundance of Glucose-6-Phosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to Metformin] which results in increased abundance of Glucose-6-Phosphate
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Glucose-6-Phosphate]
APP protein mutant form results in decreased abundance of fructose-6-phosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-6-phosphate]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of ECE1 protein] phosphoramidon decreases activity of recombinant Ece1 protein in COS cells
phosphoramidon results in decreased expression of EDN1 protein EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased activity of ECE1 protein]]; EDN1 protein inhibits the reaction [phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]]; phosphoramidon inhibits the reaction [Indomethacin results in increased expression of EDN1 protein]
phosphoramidon inhibits the reaction [AGT protein results in increased expression of EDNRA protein]; phosphoramidon inhibits the reaction [Phenylephrine results in increased expression of EDNRA protein]
phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; phosphoramidon inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]
browse the term
